How Common Is Osteopenia? Prevalence by Age and Sex

Osteopenia is remarkably common, affecting roughly four out of every ten adults worldwide when populations are pooled together in large analyses. A systematic review and meta-analysis covering studies across multiple continents estimated the global prevalence of osteopenia at about 40%, compared with about 20% for full osteoporosis.¹ Those numbers shift dramatically depending on age, sex, and where in the world you live, and the condition carries more clinical weight than many people realize.

What Osteopenia Actually Means

Osteopenia sits in a gray zone between healthy bone and osteoporosis. The World Health Organization defines it as a bone mineral density T-score between −1.0 and −2.5, measured by a type of X-ray scan called DXA (dual-energy X-ray absorptiometry).² A T-score compares your bone density to that of a healthy young adult of the same sex. A score of 0 means your bones are right at the reference average; anything below −2.5 crosses into osteoporosis. So osteopenia covers a wide band of bone thinning that hasn’t yet reached the threshold for a full osteoporosis diagnosis.

One wrinkle worth knowing: your T-score can differ depending on which body part is scanned. It’s not unusual for someone to register osteopenia at the hip but normal density at the spine, or vice versa. This discordance between measurement sites is well documented and can lead to different diagnoses from the same scanning session.³ Clinicians typically use the lowest T-score from any standard site to classify your bone status.

Prevalence in Women

Osteopenia is far more common in women than in men, and the gap widens sharply after menopause. In a large Chinese survey of more than 9,500 women, about a quarter of premenopausal participants had osteopenia, while nearly half of postmenopausal women did. Among postmenopausal women, osteopenia prevalence climbed steeply with age, from roughly 24% around age 40 to over 61% by age 75.⁴ Those numbers align broadly with Western data. A study from an Austrian menopause and osteoporosis clinic found that about 34% of the total patient population had osteopenia and roughly 14% had osteoporosis.⁵

Among older postmenopausal women specifically, osteopenia can be the single most common bone density category. A U.S.-based study of women aged 50 and over found that 48% had osteopenia at the total hip, compared with about 38% with normal density and roughly 15% with osteoporosis.⁶ In other words, once you pass 50, having some degree of bone thinning is the norm, not the exception.

The driving force behind this spike is estrogen loss. Estrogen helps keep bone-breaking cells (osteoclasts) in check while supporting bone-building cells. When estrogen drops around menopause, bone breakdown outpaces formation, and density declines rapidly for several years before settling into a slower, steady decline.⁷

Prevalence in Men

Osteopenia in men is far less studied, but it is not rare. Men build more bone mass during their teens and twenties, and they don’t experience the same abrupt hormonal cliff that women hit at menopause. Testosterone and estrogen both contribute to male bone health, and the decline in these hormones is gradual. The result is that men develop osteopenia and osteoporosis roughly a decade or two later than women on average. That said, reviews of the evidence consistently describe male osteoporosis as underscreened, underdiagnosed, and undertreated, in both primary and secondary prevention of fractures.⁸

One reason for the neglect is cultural: bone loss has long been framed as a women’s health issue. The U.S. Preventive Services Task Force recommends routine osteoporosis screening for women at 65 and for younger postmenopausal women at increased risk, but it has found insufficient evidence to recommend for or against screening men at any age.⁹ That doesn’t mean men are safe; it means researchers haven’t run enough trials in men to prove that screening improves outcomes. When men do fracture a hip, their risk of dying from complications is actually higher than it is for women.⁸

Racial and Ethnic Differences

Bone density varies meaningfully across racial and ethnic groups, which means osteopenia prevalence does too. In a U.S. analysis using national survey data, non-Hispanic Black adults had an osteopenia prevalence of about 16%, and Hispanic adults about 19%, while non-Hispanic white adults came in at roughly 26%.¹⁰ These differences are partly genetic and partly driven by differences in body composition, physical activity patterns, vitamin D metabolism, and dietary calcium intake. The clinical takeaway is that a single set of prevalence numbers doesn’t apply uniformly to every population, and the WHO T-score thresholds were originally derived from data on white postmenopausal women.

Why Osteopenia Matters More Than It Sounds

Many people hear “osteopenia” and mentally file it as “not quite a problem.” The clinical reality is different. Because osteopenia is so much more common than osteoporosis, the sheer number of fractures that happen in people with osteopenia actually exceeds the number in people with osteoporosis. A Lancet commentary put it plainly: although fracture risk is lower in osteopenic women individually, their greater numbers mean that most fractures occur in this group.¹¹

Data from a large prospective trial illustrate this clearly. Only about 6% of participants had T-scores meeting the WHO definition for osteoporosis, yet these women accounted for just 18% of osteoporotic fractures and 26% of hip fractures. Meanwhile, a broader group that included women with osteopenia and clinical risk factors experienced 45% of osteoporotic fractures and 53% of hip fractures.¹² In an Australian cost analysis, fractures in people with osteopenia accounted for half of all direct fracture treatment costs.¹³ Osteopenia, in population terms, is where the bulk of the bone-fragility problem lives.

How Quickly Osteopenia Progresses

Not everyone with osteopenia ends up with osteoporosis. The speed of progression depends heavily on where your T-score falls within the osteopenia range. A landmark study of older postmenopausal women estimated that women with mild osteopenia (T-scores just below −1.0) could wait about 17 years before fewer than 10% of them would develop osteoporosis. Women with moderate osteopenia needed re-screening in roughly five years, and those with advanced osteopenia, T-scores approaching −2.5, could transition to osteoporosis in about a year.¹⁴

Among people with additional risk factors, the timeline can be compressed. A study of chronically HIV-infected patients (a population at elevated risk for bone loss due to both the virus and antiretroviral therapy) found that about 36% of those with normal bone density progressed to osteopenia, with a median time of roughly seven years. Among those already osteopenic, about 24% progressed to osteoporosis, with a median time exceeding eight years in lower-risk patients but as short as three years in higher-risk ones.¹⁵ The takeaway: osteopenia isn’t a one-way conveyor belt toward osteoporosis, but it’s not static either, and the closer your T-score is to −2.5, the more attention it deserves.

Global Variation

Prevalence estimates swing enormously depending on geography. The systematic review mentioned earlier found that osteoporosis prevalence alone ranged from about 4% in the Netherlands to 52% in Turkey, with Africa reporting the highest continental rate and Oceania the lowest.¹ When researchers examined the disability burden of low bone mass and related fractures across 204 countries, the five countries shouldering the largest absolute burden were India, China, the United States, Japan, and Germany.¹⁶ Developing countries tended to have higher age-standardized prevalence than developed ones, and global analyses found a negative correlation between a region’s development index and its bone-loss-related disability rate from 1990 to 2021.¹⁷

Part of this variation reflects differences in nutrition, physical activity, vitamin D exposure, body size, and genetics. Part of it reflects differences in who gets scanned. In countries where DXA machines are scarce, prevalence is harder to measure accurately, and the true burden may be underestimated.

Medications and Other Secondary Causes

Age and hormonal shifts get most of the attention, but a long list of medications can accelerate bone loss and push people into osteopenia earlier than expected. Glucocorticoids (like prednisone) are the most familiar culprit, but they are far from the only one. Proton pump inhibitors used for acid reflux, certain antidepressants, anti-seizure drugs, some diabetes medications, hormone-suppressing cancer therapies, and long-term blood thinners all have documented effects on bone density.¹⁸ If you’ve been on any of these for a long time, it’s worth asking your doctor whether a DXA scan makes sense even if you wouldn’t otherwise meet the age threshold for screening.

At the cellular level, aging itself shifts the balance between bone formation and bone resorption. Bone-building cells die off more readily as you get older, while stress-response pathways inside those cells divert resources away from building new bone.¹⁹ Animal studies confirm that this decline plays out across multiple skeletal sites, with stem cells in aging bone marrow shifting their activity from making bone cells to making fat cells.²⁰ Medications that further tip this balance simply accelerate what is already an unfavorable trend.

Osteopenia in Younger Adults and Athletes

Most conversations about bone loss focus on postmenopausal women and older men, but osteopenia can show up surprisingly early. In the Chinese survey, about 21% of 18-year-old women already had osteopenia, and prevalence rose from there even before menopause.⁴ A study of young women in Saudi Arabia found that more than a third of participants had osteopenia or osteoporosis, with higher soft drink consumption, less exercise, and lower dairy intake all associated with worse bone density.²¹

Athletes might seem protected, but certain sports actually carry elevated risk. Endurance athletes and those in weight-class-sensitive sports sometimes develop relative energy deficiency in sport (RED-S), a condition where the body doesn’t take in enough calories to support its energy demands. RED-S can suppress reproductive hormones and impair bone formation.²² Elite cyclists are a well-studied example: cycling is non-weight-bearing, and when combined with low energy availability, it can produce unexpectedly low bone density. Research in professional cyclists has linked objective markers of low energy availability to reduced bone mineral density.²³ The lesson here is that exercise protects bones primarily when it involves impact or resistance, and only when the body has enough fuel to support the repair process.

Trends Over Time and the Role of Lifestyle

You might assume that younger generations, with better nutrition and healthcare access, would have stronger bones. The data are mixed. In South Korea, researchers found a concerning pattern: bone mineral density in younger postmenopausal women actually trended downward in more recent survey years, while density in older women held steady or even improved. The suspected explanation was that younger women were becoming more physically inactive. National survey data showed a significant drop in physical activity levels over time, especially among adults under 65.²⁴

This finding fits with what is known about modifiable risk factors for bone loss. Weight-bearing exercise, adequate calcium and vitamin D, and sufficient caloric intake all help maintain bone density. A meta-analysis of trials in postmenopausal women found that combining exercise with calcium and vitamin D supplementation produced meaningfully greater improvements in spine and hip bone density compared with supplementation alone.²⁵ Mechanical loading from physical activity stimulates calcium deposition in bone, making it denser and stronger, and this effect persists throughout life.²⁶ A sedentary lifestyle at any age erodes the advantage.

Who Should Get Screened

Formal screening guidelines remain narrower than the actual size of the problem. The U.S. Preventive Services Task Force recommends DXA screening for all women 65 and older, and for postmenopausal women younger than 65 who have elevated fracture risk based on clinical assessment tools like the FRAX calculator.⁹ For men, no general screening recommendation exists at any age, largely because large-scale randomized trials of screening and treatment in men are lacking.²⁷

Given how many fractures actually originate in people with osteopenia rather than osteoporosis, there is growing discussion about whether the screening net should be wider. Risk factors that might warrant earlier or broader screening include long-term use of bone-damaging medications, a family history of hip fracture, low body weight, smoking, heavy alcohol use, early menopause, or conditions like rheumatoid arthritis, celiac disease, or chronic kidney disease. If any of these apply to you, a conversation with your doctor about bone density testing is reasonable regardless of your age or sex.

The Economic Side of Bone Thinning

The financial burden of osteopenia is substantial precisely because of how common the condition is. In Australia, fractures in people with osteopenia accounted for 50% of all direct fracture treatment costs in adults 50 and older.¹³ In Germany, a projection of osteoporosis-related hip fractures estimated billions of euros in combined direct and indirect costs, a figure expected to climb as populations age.²⁸ In Mexico, researchers similarly projected a growing financial strain from low bone density as the older population expands.²⁹

These costs reflect not just fracture treatment but also rehabilitation, lost work productivity, and long-term disability. Hip fractures in particular carry a high toll: many older adults never fully regain their pre-fracture mobility, and mortality rates in the year following a hip fracture remain high. From a public health perspective, the argument for taking osteopenia seriously as a population-wide concern, rather than a mild finding on a scan, continues to strengthen.